Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

CareDx, Inc. - Common Stock (NQ:CDNA)

17.29 -1.10 (-5.98%)
Streaming Delayed Price Updated: 1:26 PM EDT, Apr 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about CareDx, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
CAREDX INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of CareDx, Inc. - CDNA
From Kahn Swick & Foti, LLC
Via Business Wire
CareDx Launches Two Expanded Indications for AlloSure Testing Services
From CareDx, Inc.
Via Business Wire
CAREDX INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of CareDx, Inc. - CDNA
From Kahn Swick & Foti, LLC
Via Business Wire
CareDx Announces Fourth Quarter and Full Year 2024 Financial Results
From CareDx, Inc.
Via Business Wire
CareDx Announces District Court Reverses Jury Decision in Patent Infringement Case Overturning Prior $96 Million Verdict
From CareDx, Inc.
Via Business Wire
Johnson Fistel has Commenced an Investigation on Behalf of CareDx, Inc. Shareholders
From Johnson Fistel, LLP
Via Business Wire
CareDx Announces Presentation of Data at 2025 Tandem Meetings Demonstrating Strong Performance of AlloHeme in Early Relapse Detection for Hematologic Malignancies
From CareDx, Inc.
Via Business Wire
CareDx to Report Fourth Quarter and Full Year 2024 Financial Results
From CareDx, Inc.
Via Business Wire
CareDx Announces Preliminary Fourth Quarter and Full Year 2024 Results
From CareDx, Inc.
Via Business Wire
CareDx to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
From CareDx, Inc.
Via Business Wire
BioMedNewsBreaks — TC BioPharm Holdings PLC (NASDAQ: TCBP) and CareDx Collaborate to Enhance TCB008 Cell Therapy Development for AML
Via Investor Brand Network
CareDx Partners with TC BioPharm to Support ACHIEVE Clinical Trial Using AlloCell for Pharmacokinetic Monitoring of Allogeneic Cell Therapy
From CareDx, Inc.
Via Business Wire
CareDx to Participate in Upcoming Investor Conferences
From CareDx, Inc.
Via Business Wire
CareDx Reports Third Quarter 2024 Results and Raises Revenue Guidance
From CareDx, Inc.
Via Business Wire
CareDx and Dovetail Genomics Announce Strategic Partnership to Drive Next Wave of Innovation in Transplant Matching with Cutting-Edge Hi-C Technology
From CareDx, Inc.
Via Business Wire
CareDx Showcases Latest Advancements Across its HLA Typing Solutions at Annual American Society for Histocompatibility and Immunogenetics Meeting
From CareDx, Inc.
Via Business Wire
CareDx Reports Preliminary Financial Results for Third Quarter 2024
From CareDx, Inc.
Via Business Wire
CareDx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From CareDx, Inc.
Via Business Wire
CareDx Appoints Jing Huang Chief Data and AI Officer
From CareDx, Inc.
Via Business Wire
CareDx to Host Investor Day on October 15, 2024
From CareDx, Inc.
Via Business Wire
CareDx Announces Closure of DOJ Investigation with No Finding of Wrongdoing
From CareDx, Inc.
Via Business Wire
CareDx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From CareDx, Inc.
Via Business Wire
CareDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From CareDx, Inc.
Via Business Wire
CareDx Appoints Keith Kennedy Chief Operating Officer and Jessica Meng Chief Commercial Officer
From CareDx, Inc.
Via Business Wire
CareDx Announces Transplant Community Secures Win Reaffirming Longstanding Medicare Coverage for AlloSure and AlloMap Testing
From CareDx, Inc.
Via Business Wire
CareDx Reports Second Quarter 2024 Results and Increases Revenue Guidance
From CareDx, Inc.
Via Business Wire
CareDx to Report Second Quarter 2024 Financial Results
From CareDx, Inc.
Via Business Wire
Landmark Independent Publication in Nature Medicine Validates CareDx AlloView AI-Enabled Risk Prediction Model and Demonstrates AlloSure Kidney Detects Subclinical Rejection in Stable Patients
From CareDx, Inc.
Via Business Wire
AI Integration and Real-World Utility of CareDx Portfolio Highlighted in New Data at the 2024 American Transplant Congress
From CareDx, Inc.
Via Business Wire
CareDx Reiterates Position that it Does Not Infringe the ‘544 Patent, Injunction Motion is Irrelevant
From CareDx, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.